Additionally, in the APP mouse model of AD, LXA4 treatment was associated with an increased ratio of IBA1 to Aβ levels, indicating a shift toward a pro‐resolving phenotype in microglia and improved cognitive function (Medeiros et al. 2013). Here, APP is linked to Alzheimer disease.